TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03506555

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic peritoneal entry technique: Veress needle versus Hasson
Description: According to randomization, the closed (Veress needle) or the open (Hasson) laparoscopic entry technique was utilized for general surgical operations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic peritoneal entry technique: Veress needle versus Hasson
Description: According to randomization, the closed (Veress needle) or the open (Hasson) laparoscopic entry technique was utilized for general surgical operations
Study: NCT04647500

Intervention type: DRUG
Group type: OTHER
Intervention: Concerta
Description: Evaluation of a treatment of Concerta over a period of 13 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Concerta
Description: Evaluation of a treatment of Concerta over a period of 13 days.
Study: NCT02984046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protein CC16
Study: NCT03793712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167 (1-2 mg/day)
Description: Fixed-flexible oral dose, tablets. Once daily. 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167 (3-4 mg/day)
Description: Fixed-flexible oral dose, tablets. Once daily. 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral dose, tablets. Once daily. 12 weeks.
Study: NCT00852995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP802-247
Description: One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP802-247
Description: One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP802-247
Description: One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HP802-247
Description: One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle)
Description: Placebo (Vehicle) consisting of:~Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution
Study: NCT00498173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
Study: NCT03380689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: - S-1 is administered orally on days 1 to 7 of a 14-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: - CPT-11 was administrated as a 90-min intravenous infusion on day 1 of a 14-day cycle. Five escalating dose levels of CPT-11 were prepared, at an initial dose of 75mg/m2/day (level 1), stepping up to 100 (level 2), 125 (level 3), 150 (level 4) or 175 (level 5) mg/m2/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: - Bevacizumab (5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 2-week cycle.
Study: NCT02634723

Intervention type: BIOLOGICAL
Intervention: Octocog alfa (recombinant human coagulation factor VIII)
Study: NCT03910556

Intervention type: DRUG
Intervention: Propofol
Description: intraoperative factors

Intervention type: DRUG
Intervention: Propofol
Description: intraoperative factors
Study: NCT02735369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% OC-10X
Description: 2% OC-10X

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study: NCT00373204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motexafin Gadolinium
Description: On Day 1 of each 3 week cycle for up to 12 cycles:~MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour.
Study: NCT01776073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Study: NCT00866307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: Undergo radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT00868946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Virazole (Ribavirin)
Description: Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.~Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).
Study: NCT02052271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal cerebellar transcranial direct current stimulation
Description: Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cathodal cerebellar transcranial direct current stimulation
Description: Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;
Study: NCT01785134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omentectomy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Gastric bypass operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass operation
Study: NCT03027739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: CART-19 cells treated
Study: NCT04476303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEY2153
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEY2153
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEY2153
Description: Capsule
Study: NCT04479111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic ileocecus-sparing right hemicolectomy
Description: The ileocecal artery(ICA) is skeletonized. The colic branch of ICA is divided and ligated. Preserve anterior cecal artery, posterior cecal artery and ileocecal branch of ICA. Divide and ligate the right colic artery(RCA) and middle colic artery(MCA) at their roots. Dissect the lymph nodes surrounding the ICA, RCA and MCA accordingly. Head-to-Head colocolic anastomois is done, with circular stapler via making an opening at the bottom of cecum.
Study: NCT00896376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT01421550

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical repair
Description: Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
Study: NCT01588717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: glycopyrrolate 2 to 6mg/day
Study: NCT04500327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drive app
Description: The Drive app will be used to monitor sleep metrics for users of CPAP therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non contact motion sensor
Description: The non contact motion sensor will be used as a reference to the Drive app i.e. Drive app overnight recordings will be compared to the non contact motion sensor overnight recordings.
Study: NCT01966133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethiodized Oil + Doxorubicin
Description: TACE using doxorubicin-lipiodol mixture
Study: NCT04336631

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention on DCP3 based strategies for Hypertension Management and Control
Description: Intervention on DCP3 based strategies for Hypertension Management and Control was developed after formative research findings and evidence built on desk review which was conducted prior to implementation of the multi-componnet strategy. It was tested and implemented in a tertiary care hospital of cardiology among hypertensive patients visiting out-patient department in Rawalpindi, Pakistan.
Study: NCT03921021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telomelysin
Description: OBP-301, the investigational product (IP) is formulated in 20 mM Tris pH 8.0, 25 mM NaCl with 2.5% glycerin, USP by volume. OBP-301 will be injected into the target tumor lesions.
Study: NCT01903512

Intervention type: PROCEDURE
Intervention: TMJ arthrocentesis
Description: lavage of the superior TMJ space with saline and sodium hyaluronate (SH)
Study: NCT02852512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacrocolpopexy
Description: Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacrocolpopexy
Description: Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture
Study: NCT01537757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: Single dose, administered as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: Single dose, administered as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: Single dose, administered as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: Single dose, administered as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: Single dose, administered as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8931
Description: Single dose, administered as oral capsules
Study: NCT02565407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
Study: NCT02537171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apatinib
Description: Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apatinib
Description: Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
Study: NCT03800654

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful Action for Pain
Description: MAP integrates formal mindfulness meditation with methods from Acceptance and Commitment Therapy and Dialectical Behavior Therapy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindful Action for Pain
Description: MAP integrates formal mindfulness meditation with methods from Acceptance and Commitment Therapy and Dialectical Behavior Therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Chronic Pain
Description: CBT-CP is the current gold standard psychosocial intervention for chronic pain and will be compared to MAP in the second arm of the study.
Study: NCT03107793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
Study: NCT00717171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurgiStim3
Description: Electrical stimulation device that provides interferential, high voltage pulsed current and neuromuscular waveforms in sequence. The device runs continuously for the first 2 days following surgery, then runs 3 times a day for 1 hour on days 3 through 42.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SurgiStim3
Description: The placebo device is programmed to run for the same amount of time, at the same schedule, using the same waveforms as the functional device over the course of the 42 days. The placebo device, however, will only increase to 80% of the patient-set amplitude after a one minute set-up period and will only turn on for 6 seconds of every minute (3s ramp up, 1s on time, 2s ramp down).
Study: NCT03711643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block
Description: 4 injections of 2 cc of lidocaine for a Periprostatic nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic nerve block
Description: 4 injections of 2 cc of lidocaine for a Periprostatic nerve block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypnosis mask
Description: The mask HYPNOS pro stimulates the imagination of the user by means of 6 diodes among 3 by eye.~Just before the introduction of ultrasound probe, the patient put the hypnotic mask and choose a session.Twenty minutes after the removal of the probe, an healthworker assess the painful patient with the visual analogue scale VAS, after this the patient fulfill the STATE- TRAIT Anxiety Inventory (STAI) form Y-A.
Study: NCT03799393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIAS (Computer Intervention Authoring Software)
Description: This is a digital application that allows families to interact with a tablet computer to receive educational information customized to the patient's age and size. allows authors to develop screening, assessment, and intervention tools for patients without requiring new programming. The CIAS intervention is programmed using tailored branching logic to allow a custom path through the intervention based on the respondent's answers. Delivery of the intervention uses a two-dimensional avatar narrator character that mimics the conversational structure of person-delivered brief interventions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Printed Discharge Instructions
Description: Patients/families will receive standard, printed discharge instructions. This is a 5 page general document from our Injury Prevention Center that describes appropriate car restraint safety for all age groups, not specific to the child enrolled.
Study: NCT02686515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single-task balance training
Description: The framework of progressive balance exercises in the single-task training will include body stability tasks (Stance activities), transitional activities (Sit to stand and walk), and body transfer tasks (Gait activities). These exercises target various systems for balance control, such as stability limits (standing with changes in base of support and weight shifting), sensory orientation (standing on compliant surfaces with eyes open and eyes closed), postural responses (reactions to balance perturbation, sit to stand and walk), and gait (treadmill walking with increasing speed).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual-task balance training
Description: Three cognitive tasks will be used for dual-task training while standing and walking: auditory discrimination tasks, verbal fluency tasks, and calculation tasks. In addition, motor tasks such as carrying a bag, holding a glass of water, alternating hand movement, carrying a tray with glasses, or getting keys out of a pocket will also be included as added tasks.
Study: NCT01452399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shave margins
Description: Partial mastectomy with shave margins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Shave Margins
Description: Partial mastectomy without shave margins.